medRxiv preprint doi: https://doi.org/10.1101/2023.01.23.23284887; this version posted January 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Dexa_manuscript_manuscript_V3_22.01.20222_1135AM_DW

Impact of Perioperative Dexamethasone in the Context of Neurosurgical Brain Metastasis Resection

- 1 David Wasilewski, MD^{1, 6}, Jan Bukatz^{1*}, Ricarda Peukert^{1*}, Zoe Shaked^{1*}, Paul Poeser¹,
- 2 Anna-Gila Karbe, MD¹, Anna-Trelinska-Finger, MA⁶, Claudius Jelgersma, MD¹, Anton
- 3 Früh, MD¹, Matthias Raspe^{2, 6}, MD², Helena Radbruch, MD⁴, David Capper MD^{4, 6}, Max
- 4 Schlaak, MD^{5, 6, 9}, Peter Thuss-Patience, MD^{6, 7, 9}, Philip Bischoff, MD^{6, 8, 10}, David Horst,
- 5 MD^{6, 8, 9, 10}, Marcel Krenzke¹¹, Ran Xu, MD^{1, 10}, Felix Ehret, MD^{3, 6, 10}, David Kaul, MD^{3, 6, 10},
- 6 Martin Misch, MD^{1, 6}, Lars Bullinger, MD^{6, 12}, Nikolaj Frost, MD^{2, 6}, Peter Vajkoczy, MD^{1,}
- 7 ⁶. Julia Onken. MD^{1, 6, 9, 10}
- ¹Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of
 Neurosurgery, Berlin, Germany.
- ²Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of
 Infectious Diseases and Pulmonary Medicine, Berlin, Germany.
- ³Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of
 Radiation Oncology, Berlin, Germany
- ⁴Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of
 Neuropathology, Berlin, Germany.
- ⁵Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of
 Dermatology, Venerology and Allergology, Berlin, Germany.
- 18 ⁶Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Charité 19 Comprehensive Cancer Center, Berlin, Germany.
- ⁷Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of
 Hematology, Oncology and Cancer Immunology, Berlin, Germany
- ⁸Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of
 Pathology, Berlin, Germany
- ⁹ Charité Universitätsmedizin Berlin, Berlin, Germany; German Cancer Consortium (DKTK), partner site Berlin, and German Cancer
 Research Center (DKFZ), Heidelberg, Germany
- 26 ¹⁰Berlin Institute of Health at Charité Universitätsmedizin Berlin, Berlin, Germany
- ¹¹Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Medizinisches
 Zentralarchiv, Berlin, Germany
- 29

- 30 ¹²German Cancer Consortium (DKTK), Heidelberg, Germany; Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität
- 31 Berlin, Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Cancer Immunology, Berlin, Germany.
- 32
- Corresponding Authors: <u>peter.vajkoczy@charite.de</u> and <u>david.wasilewski@charite.de</u>, Charité Campus Mitte, Charitéplatz 1, 10117 Berlin,
 Germany
- 35 *contributed equally

36 manuscript word count: 3591

- 37 **Keywords:** lung cancer, breast cancer, melanoma, renal cell cancer, esophageal cancer,
- 38 brain metastasis resection, cumulative dexamethasone, overall survival
- 39

40 Abstract

Background: Patients with brain metastases that undergo brain metastasis resection
 regularly receive perioperative dexamethasone. We sought to evaluate whether perioperative
 dexamethasone in brain metastases is linked to survival.

44 Methods: Retrospective data on perioperative dexamethasone dosage in resected brain 45 metastasis patients at three hospital sites of the Charité from 2010-2022 were collected. Cutoff values for cumulative perioperative dexamethasone dose as a continuous predictor 46 47 variable for survival were determined using maximally selected rank statistics. Patients were 48 dichotomized based on determined cut-offs of cumulative dexamethasone (pre-operative: < 49 40 mg vs \ge 40 mg; post-operative: < 180 mg vs \ge 180 mg) and pre- and postoperative: < 281 50 mg vs \geq 281 mg). Medical records included baseline demographic, radiological, 51 histopathological and treatment-related characteristics. Based on cut-off values for 52 dexamethasone downstream statistical analyses included Kaplan-Meier, Cox proportional 53 hazards regression for overall survival with adjustment for potential confounders including 54 age, gender, Karnofsky performance status and presence of extracranial metastasis via 55 propensity score matching.

56 **Results:** 539 patients were included. Median follow-up time was 58,97 months. After 57 adjusting for age, gender, Karnofsky performance status and presence of extracranial 58 metastasis patients with higher cumulative perioperative dexamethasone (≥281 mg) showed

shorter survival (HR: 1.47 (1.20-1.80, p<0.001) as compared to patients with lower cumulative doses (<281 mg). This effect remained significant after correction for patients that died within 2 months after resection and for patients with KPS below 50% and, independently from this approach performing propensity score matched-based analysis of the total cohort of patients,

63 respectively.

64 **Conclusion:** Cumulative perioperative dexamethasone is associated with decreased survival 65 in the context of brain metastasis resection. Strict dosage, down taper or methods reducing 66 corticosteroid dependency should be regularly evaluated in clinical practice in patients with 67 brain metastases.

68 (278 words)

- 69
- 70
- _.
- 71
- 72
- 73
- 74
- 75
- 76

77 BACKGROUND

⁷⁸ Up to 50% of cancer patients develop brain metastasis within the course of disease^{1,2}. Brain ⁷⁹ metastases are in general associated with a bad prognosis, however a subset of these ⁸⁰ patients with good clinical performance or good Karnofsky performance status (KPS), ⁸¹ surgically accessible and/or symptomatic brain metastases are regularly undergoing ⁸² extensive treatment including neurosurgical brain metastasis resection followed by ⁸³ radiotherapy (RTx)³⁻⁵. Apart from advances in local therapy (e.g. stereotactic radiosurgery

84 (SRS)), systemic treatment approaches have experienced some major changes. Adjuvant 85 therapies have shifted from post-operative RTx and chemotherapy (CTx) to post-operative 86 RTx with targeted therapies including small molecule inhibitors or checkpoint inhibition (CPI)³⁻ 87 ⁷. Similar to glioblastoma treatment, patients with symptomatic brain metastases that undergo 88 neurosurgical treatment with craniotomy and microsurgical brain metastasectomy regularly 89 receive pre- and postoperative dexamethasone to treat perifocal edema to alleviate 90 neurological symptoms^{8,9}. Yet, dexamethasone use may be associated with significant 91 adverse effects and immunosuppression^{10,11}. In addition, there is ample evidence from the field of glioblastoma to suggest that pre- and postoperative dexamethasone is associated 92 93 with worse overall survival (OS) as recently shown in several retrospective studies¹²⁻¹⁴. No 94 larger randomized-controlled prospective trials have been conducted on this matter up to 95 now. This holds also true for patients with brain metastases. Importantly, systematic studies 96 evaluating potential adverse effects of dexamethasone including its impact on OS, other 97 complications such as negative impact of perioperative dexamethasone on post-operative 98 treatments including CPI could provide important information and generate more evidence for 99 decision-making with respect to dexame thas one dosage regimens. Given the paucity of data, 100 we aimed to investigate whether perioperative dexamethasone (i.e. administered in the pre-101 operative period, post-operative period and in both periods) adversely affects clinical outcome 102 patients undergoing brain metastasectomy. Real-world data on perioperative in 103 dexamethasone dosage may aid in further evaluating dexamethasone dosage and initiating 104 randomized-controlled studies to find an optimal dosage regimen for these patients. This 105 retrospective. comparative effectiveness study describes detailed perioperative 106 dexamethasone dosage in a large cohort of patients who underwent brain metastasectomy 107 (n=539). Further the study provides descriptive information on demographics, radiological 108 and histological features as well as treatment-related features after brain metastasis 109 resection. To find optimal cut-off values or cut-points based on different settings or time 110 windows for dexamethasone dosing in the context of metastasectomy, we used a well-known 111 cut-off estimation model by Hothorn and Lausen called the maximally selected rank statistic. 112 Using this model, we examined the association between cumulative preoperative, 113 postoperative, and total dexamethasone dose and clinical outcome in conjunction with a 114 downstream descriptive and inferential statistics with overall survival as the primary outcome 115 ¹⁵. (422 words)

116

117 METHODS

118 **1.1 Patient cohort and study variables**

119 For this retrospective study all patients with neurosurgically resected brain metastases 120 treated at all three sites of Charité-Universitätsmedizin Berlin in the period from January 121 2010 to December 2022 were included. Data censoring was 1st of December 2022. Patient 122 data were identified as previously described using an institutional database (SAP, Walldorf, 123 Germany) as well as the Charité Comprehensive Cancer Center (CCCC) Registry¹⁶. 124 Patients with a histopathological confirmation of an intracerebral manifestation of non-small 125 cell lung cancer (NSCLC), breast cancer, melanoma, renal cell carcinoma (RCC), colorectal 126 cancer (CRC), esophageal cancer or gastric cancer or unknown primary tumor were 127 included. This study is in accordance with the ethical standards outlined in the Declaration 128 of Helsinki and was approved by the research ethic board at the Charité (EA1/399/20)¹⁶. 129 Exclusion criteria are displayed in the consort diagram (**Figure 1**). Exposure to 130 perioperative dexamethasone was defined as follows: pre-operative dexamethasone 131 included cumulative dexamethasone dosage in mg from day thirteen before the day of 132 operation (-13d) till the day of operation (d0), post-operative dexamethasone included 133 cumulative dexamethasone dosage in mg from day one after the day of operation (1d) till 134 day thirteen after day of operation (d13), and pre- and postoperative dexamethasone hence 135 was defined as cumulative dexamethasone dosage in mg from day thirteen before the day 136 of operation (-13d) till day thirteen after day of operation (d13) (Figure 1). OS represented the primary outcome of this study and was defined as time from brain metastasis resection 137 138 until death from any cause. Baseline was defined as day first brain metastasis resection in each patient's history; baseline characteristics were selected according to previous 139 140 retrospective studies ^{6,7,15}. KPS was assessed after first brain metastasis resection and 141 dichotomized in good (\geq 70%) and bad (<70%). Presence of underlying other diseases was 142 defined as presence of cardiovascular diseases, chronic lung, renal or liver diseases and 143 was dichotomized in either not present or present. Radiological baseline characteristics 144 included anatomical localization of resected brain metastases, number of brain metastases 145 at baseline, presence of extracranial metastases at baseline and were based on reports 146 from board-certified radiologists (eTable 1a-b, eTable 2 a-b in the online supplements). 147 Tumor volumes and associated edema volumes were quantified using a semi-automated 148 3D rendering algorithm in iPlannet (Brainlab, Munich, Germany) using the SmartBrush tool

149 (T1-weighted images for tumor and FLAIR-images for edema measurements). Only the 150 resected lesion was quantified; in case of multiple lesions no addition of tumor or edema 151 volumes was performed. Treatment-related features included the total number of brain 152 metastasis resections, resection of primary tumor mass, administered systemic treatment 153 modalities before brain metastasis resection and adjuvant therapy after brain metastasis 154 resection. Information on systemic treatment and radiotherapy before or after first brain 155 metastasis resection at our institution was retrieved from our database and patient records 156 similarly to our previous study¹⁶ (eTable 1a-d in the online supplements). Follow-up data 157 were retrieved from the registry from the Charité Comprehensive Cancer Center (CCCC) 158 and obtained until December 1st 2022. In NSCLC driver mutational status or included driver 159 mutational status of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or c-ros oncogene (ROS1) translocations were regularly assessed after 2015. In 160 161 melanoma v-raf murine sarcoma viral oncogene homolog B1 (BRAF) from 2014 onwards 162 and human epidermal growth factor receptor 2 (Her2) status in case of breast cancer; 163 thyroid transcription factor-1 (TTF1) status was regularly documented, whereas 164 progesterone receptor (PR) and estrogen receptor (ER) status were documented in case 165 breast cancer brain metastasis was suspected. Further histopathological information 166 retrieved from patient records included Ki67 index and programmed death ligand 1 (PD-L1) 167 tumor proportion score (TPS) of resected brain metastasis tissue (eTable 1a-d). Institutional 168 pathological review was mandatory, all resected specimens were reviewed by board-169 certified neuropathologists for diagnosis. Chi-square test of independence was used to 170 analyze the frequency table for categorical variables. Non-parametric Wilcoxon rank sum 171 test was used for comparing two means not normally distributed data of this dataset; when 172 expected count was below 5 Fisher's exact test was used. (656 words)

173 **1.2 Statistical analysis**

- 174 We used R studio (Version 2021.09.2, R Foundation for Statistical Computing, Inc, Boston,
- 175 USA) to compute descriptive and inferential statistics as in our previous study¹⁵. The
- 176 gtsummary package was used to describe tabular data of our patient cohort, including
- 177 categorical and numerical variables (https://cran.r-
- 178 project.org/web/packages/gtsummary/index.html). Median OS was estimated by means of
- 179 Kaplan-Meier analysis with confidence interval bands being displayed in the respective
- 180 figures: Plotting was performed using the survival (https://cran.r-

181 project.org/web/packages/survival/index.html)and survminer package (https://cran.rproject.org/web/packages/survminer/index.html). The prognostic value of each variable was 182 183 tested using the log-rank estimator. Univariable and multivariable Cox regression modeling 184 served to assess the effect of one or the simultaneous effects of multiple clinical variables 185 on OS and was done using the survminer package. Cut-off values for cumulative perioperative dexamethasone dose as a continuous predictor variable for survival were 186 187 evaluated and determined via an algorithm using maximally selected rank statistics 188 implemented in the maxstat package (https://cran.r-189 project.org/web/packages/maxstat/index.html). Patient that were included in this study 190 includes the total cohort "all" (N=539), referred to as COHORT A and a subcohort after 191 excluding patients with less than 2 months OS and patients with KPS less than 50% named 192 "2months and KPS<50excl", which was termed as COHORT B. The effect of perioperative 193 Dexamethasone on survival was also reevaluated via 1:1 (nearest-neighbor) propensity 194 score matching as described in our previous work¹⁵. Propensity score matching involved the 195 following baseline covariates: age, gender, KPS (dichotomized into <70% or "bad" and \geq 196 70% or "good") and presence of extracranial metastases. The matched cohort is henceforth 197 referred to as COHORT C. Kaplan-Meier analyses were performed after applying different 198 cutpoints and dichotomizing patients into subgroups according to optimal cut-point value for 199 pre-operative dexamethasone, postoperative dexamethasone and pre- and postoperative 200 (total) dexamethasone. Further R packages used, included common analytical packages 201 such as *dplyr*, *tidyverse*. We conducted univariable and multivariable analysis for both 202 datasets (COHORT A, B and C) for OS as a main endpoint adjusting for potential 203 confounders such as age, gender, (KPS) and presence of extracranial metastasis was 204 performed. Data collection was done with Microsoft Excel (Version 14.3.9, Microsoft Inc., 205 Redmond, USA). Graphpad Prims (Version 9, Graphpad Software, Inc., San Diego, USA) was used for plotting Supprentary figure 2b. A p-value of < .05 was considered significant 206 207 with p-values being two-sided. R code and raw data will be made available at github upon 208 request. (384 words)

209

210

211 2 **RESULTS**

212 **2.1 Baseline characteristics**

213 Characteristics of patients with cancer brain metastases that met the inclusion criteria 214 COHORT A (n=539) are shown in the supplementary material section (Figure 1, eTable 1ad in the online supplements). There were 260 (48%) male and 279 (52%) female 215 216 individuals in the total cohort of patients. Median age was 64 years (55-72, IQR). Most 217 common symptoms associated with brain metastases were sensory-motor symptoms (21%), 218 vertigo or dyscoordination (20%) and headache (12%). Sixty-two percent of patients had a 219 good postoperative KPS (\geq 70%), whereas 38% of patients had a bad KPS (<70%). 220 Predominant histopathology included brain metastases due to NSCLC, 93 (17%) were due 221 to breast cancer, 91 (17%) were due to melanoma and 33 (6,1%) were due to SCLC. Renal 222 cell cancer accounted for 4.8%. Two hundred eighty-nine (45%) patients were pre-treated 223 with systemic anti-tumor therapy before first brain metastasis resection (baseline), and 238 224 patients (55%) were treatment naïve. Other radiological, histopathological, and treatment-225 related characteristics of this collective are summarized in supplementary materials (eTable 226 1a-d). Median follow-up time (IQR) was 58.97 months (31.97-89.17 months). Cumulated 227 median OS of the COHORT A (n=539) was 13.3 month (95% CI: 12.1 - 15.2) and 11.4 (95% 228 CI: 10.2 – 13.2) (p=0.049) for the COHORT B (eFigure 1, eTable 2a-d in the online 229 supplements). (209 words)

230

231 2.2 Dexamethasone dosage regimens and association of dexamethasone with overall 232 survival

The median dexamethasone dose was 80 mg for the pre-operative period, 96 mg for the 233 234 postoperative period and 190 mg for the total pre- and post-operative period for the COHORT 235 A and 80 mg for the pre-operative period, 84 mg for the postoperative period and 187 mg for 236 the total pre- and postoperative period for the COHORT B, respectively (Table 1a, 1b). The 237 cumulative total dexamethasone dose prescribed during the pre-operative and post-operative 238 period did not correlate with age, KPS or histopathological markers such as Ki67 or PD-L1 239 TPS, tumor volume or edema volume in COHORT A (eFigure 2a, b in the online 240 supplements). 38 patients did not receive dexamethasone at all. Interestingly, within COHORT A and COHORT B no difference in OS was observed between patients that did not 241 242 receive perioperative dexamethasone (-DEXA) vs. those patients that did receive

perioperative dexamethasone (+DEXA) (eFigure 3a, b in the online supplements).
Similarly, we did not observe any differences in OS within both cohorts when a cut-off of 8
mg dexamethasone daily was used to dichotomize patients during the pre-operative and postoperative period (eFigure 3c, d in the online supplements) (188 words).

247 2.3 Cutpoints for perioperative Dexamethasone dosage regimens and association 248 with overall survival

249 Next, cutpoint for cumulative perioperative dexamethasone (i.e. pre-operative, post-operative 250 as well as pre- and postoperative or total) were evaluated in terms of its association as a 251 predictor variable for OS. Cutpoint values for COHORT A and B in the pre-, postoperative 252 phase are given in table 1a-c. As for a cutpoint of cumulative dexamethasone in the pre-253 operative period for COHORT A (40 mg) and COHORT B (184 mg) there were significant 254 differences in median OS between patients with < 40 mg and \geq 40 mg and < 184 mg and \geq 255 184, respectively (eFigure 3b in the online supplements). In contrast, only the cutpoint for 256 postoperative dexamethasone dosage for COHORT A (180 mg) showed a significant 257 association with OS, whereas for COHORT B the established cutpoint (180 mg) did not result 258 in a significant difference in OS when comparing two dichotomized patient groups (eFigure 259 **3b in the online supplements**). As for the cumulative dexamethasone dose in the pre- and 260 post-operative period patients of COHORT A were dichotomized into two groups each: 261 patients with < 281 mg showing a median OS of 12.9 months (95% CI: 11.0-15.2) vs. those 262 patients with \geq 281 mg cumulative dexamethasone in the pre- and postoperative period with 263 an OS of 8.43 months (95% CI: 5.6-10.9) (p=0.0012). For COHORT B optimal cutpoint for 264 the dexamethasone dose in the pre- and postoperative period was 294 mg of post-operative 265 dexamethasone: patients with < 294 mg cumulative dexamethasone showed a median OS of 266 14.7 months (95% CI: 12.90-18.2) vs. patients with \geq 294 mg cumulative dexamethasone in 267 the post-operative period with an OS of 10.6 months (95% CI: 8.43-13.6) (p=0.0086) (Figure 268 2, 3). Additionally, we performed a 1:1 propensity score matching (PSM) for covariate 269 balancing for the total cohort of patients (COHORT A), which resulted in COHORT C with 131 270 matched patients per group. Here, patients that received <281 mg cumulative 271 dexamethasone in the perioperative period had a significantly higher OS (13.5 months; 95%) 272 CI: 10.9-17.9) than those patients that received \geq 281 mg perioperative dexamethasone that

273 showed an OS of 8.3 months (95% CI: 5.37-10.9) (p=0.0072) (eFigure 4, 5 in the online

274 supplements). (355 words)

275 **2.4** Univariable and multivariable analysis to identify prognostic factors

276 On univariable analysis there was a statistically significant association between the 277 cumulative perioperative dexamethasone dose and median OS in both cohorts COHORT A ([HR] 1.52, 95% CI: 1.25-1.85, p<0.001) and COHORT B ([HR] 1.38, 95% CI: 1.08-1.76, 278 279 p=0.009). Multivariable Cox regression for perioperative dexamethasone and covariates which were considered as potential confounders (i.e. age, gender, KPS and presence of 280 281 extracranial metastasis at baseline) showed that high perioperative ("total") dexamethasone 282 was interpedently associated with shorter OS in case of COHORT A ([HR] 1.47, 95% CI: 1.20-283 1.80, p<0.001) as well as the subgroup COHORT B ([HR] 1.35, 95% CI: 1.09-1.68, p=0.007) 284 (Table 2a). Other independent prognostic factors for both cohorts were age and KPS (Table 285 **2b**). Importantly, also for the matched dataset of patients within the whole patient cohort 286 (COHORT C) stratified into patients with < 281 mg perioperative dexamethasone and patients 287 with \geq 281 mg cumulative dexamethasone in the pre- and postoperative period showed that 288 dexamethasone was an independent prognostic factor associated with OS ([HR] 1.46, 95% CI: 1.11-1.92, p=0.012) (Table 2c). Mean standard differences are displayed in eFigure 3 in 289 290 the supplements. (179 words)

291

292 DISCUSSION/CONCLUSION

293 Corticosteroids such as dexamethasone are a standard drug in the treatment of patients with 294 brain metastases. They are used to control the mass effect of perifocal tumor edema and the 295 resulting neurologic deficitsts¹². Treatment recommendations in this context lack evidence and are primarily based on expert opinion and few retrospective data^{3, 4, 10}. With advent of 296 297 immunotherapy or CPI dexamethasone dosage and down-taper schemes will likely gain 298 importance as for other entities or situations. However, one randomized study with patients 299 with brain metastases receiving either 4 mg, 8 mg or 16 mg dexamethasone daily reported 300 improvement of symptoms by means of KPS at day 7 and day 28, respectively¹⁸. Importantly, 301 there is a marked variability between centers and treating physicians in terms of 302 dexamethasone recommendations (e.g. initiation and down tapering)^{9, 12, 19}. In this

303 retrospective, comparative effectiveness study we characterize the dosage of 304 dexamethasone and its impact on survival in patients that underwent brain metastasis 305 resection. Here, a cutpoint estimation method was used to evaluate optimal value selection 306 for survival prediction of pre-operative, postoperative and total dexamethasone. Pre-operative 307 dexamethasone, but not postoperative dexamethasone showed an association to OS in the 308 whole cohort of patients with resected brain metastases. Maximally selected rank statistics 309 were performed for pre-operative, postoperative and total (pre- and postoperative) 310 dexamethasone dosage with the total dexamethasone displaying the strongest association 311 with OS resulting in a cut-point of 281 mg. Patients receiving a high total cumulative 312 dexamethasone dose (i.e., patients receiving ≥ 281 mg) showed significantly reduced OS-an 313 effect that was confirmed in a subgroup analysis of patients after applying exclusion criteria 314 (i.e., exclusion of patients with short-term survival < 2 months or patients with postoperative 315 KPS < 50%) (Figure 2, 3). These observations could be further confirmed by multivariable 316 Cox regression analysis for unmatched data as well as for matched data after performing 317 PSM where dexamethasone with a cut-point of 281 mg in the total cohort was significantly 318 associated with an increased hazard for death (Figure 2, 3). In general, our observations are 319 in line with previously published research in the context of perioperative dexamethasone in 320 Glioblastoma patients. Here, the sum of cumulative dexamethasone doses in the pre-321 operative and post-operative period seems to have impact on OS as reported previously. For 322 instance, Zhou et al. demonstrated in a single-center PSM study that postoperative day (POD) 0 to 21 dexamethasone dosage correlated with overall survival¹⁷. Interestingly, Medikonda et 323 324 al. recently showed that that pre-operative, but not post-operative or pre- and postoperative 325 Dexamethasone dosage in Glioblastoma patients was linked to shorter OS and reported a 326 hazard ratio of 3.0 (95% CI: 0.9-9.4). In contrast, the effect of combined pre- and post-327 operative dexamethasone on survival was less pronounced in our cohort [HR] 1.47, 95% CI: 328 1.20-1.80, p<0.001). Additionally, upon stratification into subgroups of dexamethasone intake 329 (cumulative pre-operative, postoperative and perioperative (total) dexamethasone intake), we 330 only observed total dexamethasone to be associated with OS. Interestingly, there was no 331 significant correlation between cumulative dexamethasone dose and tumor volume or edema 332 volume (eFigure 2a in the supplements), which is in contrast to the observation from Zhou and colleagues for glioblastoma¹⁷. Limitations of this study include the retrospective nature of 333 334 the data originating from a retrospective and prospective brain metastasis registry. In contrast 335 to other studies, we mainly focused on inpatient records to assure data quality although 336 insufficient data capture and entry in patient files can lead to bias as those patients with 337 insufficient documentation of dexamethasone doses were excluded (Figure 1). Although we 338 performed a PSM for prognostic clinical covariates such as age, and KPS as well as 339 extracranial disease burden, there are certainly other confounding factors we do not consider 340 into the matching process in this study, which include tumor volume and edema volume. 341 These however are of prognostic value and were not considered into the matching process. 342 Additionally, larger patient cohorts from multicenter registries with standardized 343 documentation of dexamethasone dosage would be necessary to further investigate the role 344 of dexamethasone and its impact on patient outcome. This study consists only of surgical 345 patients which tend to be clinically symptomatic. Therefore, patients that did not undergo 346 surgery were excluded from this study. Our study has potential implications with respect to 347 the efficacy of CPI in patients with brain metastases that may be candidates to receive CPIs after brain metastasis resection and RTx^{20-23} . In this regard in patients with metastatic disease 348 349 several retrospective studies indicated that timing of initiation of corticosteroids may influence 350 therapy response to CPI; for example, Maslov and colleagues showed that patients treated 351 with corticosteroids within 2 months of initiation with CPI showed significantly shorter OS than 352 patients receiving corticosteroids after 2 months of initiation of treatment with CPIs²². Future 353 prospective, randomized-controlled and interdisciplinary studies should systematically 354 evaluate the benefit and complications or impact on OS but also on progression-free survival 355 according to the Response Assessment in Neuro-Oncology Brain Metastasis (RANO-BM) 356 criteria in different tumor entities. Additionally, exploratory endpoints, serum and tissue-based 357 biomarker studies of resected brain metastases pre-exposed to dexamethasone should be 358 initiated and could aid in gaining insights into the changes of the systemic and local tumor immune microenvironment in these patients²⁴⁻²⁶. This would also be informative for future 359 360 clinical trials recruiting patients with brain metastases since patients with brain metastases 361 are finally becoming more and more included in clinical trials independent of the tumor type. 362 These studies could help in better understanding the role of perioperative dexamethasone or 363 corticosteroids in terms of patient outcome, complications, or predicting the impact on post-364 operative "adjuvant" treatment including upcoming immunotherapy or CPIs. (920 words) 365

366 Figures and Tables

367	See	below to see the main figures and tables and separate word file including supplementary
368	figur	es "2. supplementary figures and material_08.01.2022_1334PM_DW".
369		
370		
371	Lite	rature
372	1.	Brain metastasis. Boire A, Brastianos PK, Garzia L, Valiente M.Nat Rev Cancer. 2020
373		Jan;20(1):4-11. doi: 10.1038/s41568-019-0220-y. Epub 2019 Nov
374		28.PMID: 31780784
375		
376	2.	Advances in the management of breast cancer brain metastases. Sammons S, Van
377		Swearingen AED, Chung C, Anders CK.Neurooncol Adv. 2021 Nov 27;3(Suppl 5):v63-
378		v74. doi: 10.1093/noajnl/vdab119. eCollection 2021 Nov.PMID: 34859234
379		
380	3.	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current
381		management and future directions. Aizer AA, Lamba N, Ahluwalia MS, Aldape K, Boire
382		A, Brastianos PK, Brown PD, Camidge DR, Chiang VL, Davies MA, Hu LS, Huang RY,
383		Kaufmann T, Kumthekar P, Lam K, Lee EQ, Lin NU, Mehta M, Parsons M, Reardon
384		DA, Sheehan J, Soffietti R, Tawbi H, Weller M, Wen PY.Neuro Oncol. 2022 Oct
385		3;24(10):1613-1646. doi: 10.1093/neuonc/noac118.PMID: 35762249
386		
387	4.	EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of
388		patients with brain metastasis from solid tumours. Le Rhun E, Guckenberger M, Smits
389		M, Dummer R, Bachelot T, Sahm F, Galldiks N, de Azambuja E, Berghoff AS, Metellus
390		P, Peters S, Hong YK, Winkler F, Schadendorf D, van den Bent M, Seoane J, Stahel
391		R, Minniti G, Wesseling P, Weller M, Preusser M; EANO Executive Board and ESMO
392		Guidelines Committee. Ann Oncol. 2021 Nov;32(11):1332-1347. doi:
393		10.1016/j.annonc.2021.07.016. Epub 2021 Aug 6.PMID: 34364998
394		
395	5.	Radiation Therapy for Brain Metastases: A Systematic Review. Garsa A, Jang JK,
396		Baxi S, Chen C, Akinniranye O, Hall O, Larkin J, Motala A, Hempel S.Pract Radiat
397		Oncol. 2021 Sep-Oct;11(5):354-365. doi: 10.1016/j.prro.2021.04.002. Epub 2021 Jun
398		9.PMID: 34119447

-	-	-
2	O	O)
J	7	フ

- 400 6. Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward 401 Immunotherapy-Mediated Systemic Control, Alvarez-Breckenridge C, Giobbie-Hurder 402 A, Gill CM, Bertalan M, Stocking J, Kaplan A, Nayyar N, Lawrence DP, Flaherty KT, 403 Shih HA, Oh K, Batchelor TT, Cahill DP, Sullivan R, Brastianos PK.Oncologist. 2019 404 May;24(5):671-679. doi: 10.1634/theoncologist.2018-0306. Epub 2019 Feb 405 22.PMID: 30796152 406 407 7. Melanoma brain metastasis presentation, treatment, and outcomes in the age of 408 targeted and immunotherapies. Bander ED, Yuan M, Carnevale JA, Reiner AS, 409 Panageas KS, Postow MA, Tabar V, Moss NS.Cancer. 2021 Jun 15;127(12):2062-410 2073. doi: 10.1002/cncr.33459. Epub 2021 Mar 2.PMID: 33651913 411 412 8. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-413 Oncology Working Group. Arvold ND, Armstrong TS, Warren KE, Chang SM, DeAngelis LM. Blakeley J. Chamberlain MC. Dunbar E. Loong HH. Macdonald DR. 414 415 Reardon DA, Vogelbaum MA, Yuan Y, Weller M, van den Bent M, Wen PY.Neuro 416 Oncol. 2018 Jun 18;20(7):897-906. doi: 10.1093/neuonc/noy056.PMID: 29788429 417 418 9. Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Lim-Fat MJ, Bi 419 WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke 420 U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, 421 Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, 422 Nabors LB, Navak L, Reardon DA, Wen PY.Neurosurgery. 2019 Sep 1:85(3):E607-423 E608. doi: 10.1093/neuros/nyz186.PMID: 31215634 424 425 10. Corticosteroids in brain cancer patients: benefits and pitfalls. Dietrich J, Rao K, 426 Pastorino S, Kesari S.Expert Rev Clin Pharmacol. 2011 Mar;4(2):233-42. doi: 427 10.1586/ecp.11.1.PMID: 21666852 428 11. Dexamethasone-induced immunosuppression: mechanisms and implications for 429 430 immunotherapy. Giles AJ, Hutchinson MND, Sonnemann HM, Jung J, Fecci PE,
- 431 Ratnam NM, Zhang W, Song H, Bailey R, Davis D, Reid CM, Park DM, Gilbert MR.J

432 Immunother Cancer. 2018 Jun 11;6(1):51. doi: 10.1186/s40425-018-0371-

- 433 **5.PMID: 29891009**
- 434

435 The role of steroids in the management of brain metastases: a systematic review and 12. 436 evidence-based clinical practice guideline. Ryken TC, McDermott M, Robinson PD, 437 Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, 438 Linskey ME, Loeffler JS, Mehta MP, Mikkelsen T, Olson JJ, Paleologos NA, Patchell 439 RA, Kalkanis SN.J Neurooncol. 2010 Jan;96(1):103-14. doi: 10.1007/s11060-009-440 0057-4. Epub 2009 Dec 3.PMID: 19957014 441 442 13. Steroids use and survival in patients with glioblastoma multiforme: a pooled analysis. 443 Petrelli F, De Stefani A, Ghidini A, Bruschieri L, Riboldi V, Dottorini L, Iaculli A, 444 Zaniboni A, Trevisan F.J Neurol. 2021 Feb;268(2):440-447. doi: 10.1007/s00415-020-445 09731-5. Epub 2020 Jan 30.PMID: 32002651 446 447 14. Corticosteroids compromise survival in glioblastoma. Pitter KL, Tamagno I, Alikhanyan 448 K, Hosni-Ahmed A, Pattwell SS, Donnola S, Dai C, Ozawa T, Chang M, Chan TA, 449 Beal K, Bishop AJ, Barker CA, Jones TS, Hentschel B, Gorlia T, Schlegel U, Stupp R, 450 Weller M, Holland EC, Hambardzumyan D.Brain. 2016 May;139(Pt 5):1458-71. doi: 451 10.1093/brain/aww046. Epub 2016 Mar 28.PMID: 27020328 452 453 Lausen, B.; Hothorn, T.; Bretz, F.; Schumacher, M. Assessment of Optimal Selected 15. 454 Prognostic Factors. Biometrical J. 2004, 46, 364–374 455 456 16. Effectiveness of Immune Checkpoint Inhibition vs Chemotherapy in Combination With 457 Radiation Therapy Among Patients With Non-Small Cell Lung Cancer and Brain 458 Metastasis Undergoing Neurosurgical Resection. Wasilewski D, Radke J, Xu R, Raspe 459 M, Trelinska-Finger A, Rosenstock T, Poeser P, Schumann E, Lindner J, Heppner F, 460 Kaul D, Suttorp N, Vajkoczy P, Frost N, Onken J.JAMA Netw Open. 2022 Apr 1;5(4):e229553. doi: 10.1001/jamanetworkopen.2022.9553.PMID: 35486401 461 462 463 Impact of postoperative dexamethasone on survival, steroid dependency, and 17.

464 infections in newly diagnosed glioblastoma patients. Mistry AM, Jonathan SV,

465		Monsour MA, Mobley BC, Clark SW, Moots PL.Neurooncol Pract. 2021 Jun
466		23;8(5):589-600. doi: 10.1093/nop/npab039. eCollection 2021 Oct.PMID: 34594571
467		
468	18.	Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic
469		brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Vecht CJ,
470		Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL.Neurology. 1994
471		Apr;44(4):675-80. doi: 10.1212/wnl.44.4.675.PMID: 8164824
472		
473	19.	Practice Variation in Perioperative Steroid Dosing for Brain Tumor Patients: An
474		International Survey. Jessurun CAC, Hulsbergen AFC, Lamba N, Nandoe Tewarie
475		RDS, Smith TR, Broekman MLD.World Neurosurg. 2022 Mar;159:e431-e441. doi:
476		10.1016/j.wneu.2021.12.067. Epub 2021 Dec 24.PMID: 34958992
477		
478	20.	Dexamethasone-induced immunosuppression: mechanisms and implications
479		for immunotherapy. Giles AJ, Hutchinson MND, Sonnemann HM, Jung J, Fecci PE,
480		Ratnam NM, Zhang W, Song H, Bailey R, Davis D, Reid CM, Park DM, Gilbert MR.J
481		Immunother Cancer. 2018 Jun 11;6(1):51. doi: 10.1186/s40425-018-0371-
482		5.PMID: 29891009
483		
484	21.	Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with
485		advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective
486		biomarker-based study. Javier GC, Alberto I, Azucena GNE, Iván V, Débora M, David
487		P, Laura A, Andrea MS, Esther S, Oleguer C, Paula B, Laura M, Nuria V, Miquel N,
488		Patricia G, Barbara A, Neus B, Tamara S, Manel J, Aleix P, Francesco S.Cancer
489		Immunol Immunother. 2023 Jan 10. doi: 10.1007/s00262-022-03360-9. Online ahead
490		of print.PMID: 36625938
491		
492	22.	Timing of steroid initiation and response rates to immune checkpoint inhibitors in
493		metastatic cancer. Maslov DV, Tawagi K, Kc M, Simenson V, Yuan H, Parent C,
494		Bamnolker A, Goel R, Blake Z, Matrana MR, Johnson DH.J Immunother Cancer. 2021
495		Jul;9(7):e002261. doi: 10.1136/jitc-2020-002261.PMID: 34226279
496		

- 497 23. Use of First-Line Immune Checkpoint Inhibitors and Association With Overall Survival
- 498 Among Patients With Metastatic Melanoma in the Anti-PD-1 Era. Lamba N, Ott PA,
- 499 Iorgulescu JB.JAMA Netw Open. 2022 Aug 1;5(8):e2225459. doi:
- 500 10.1001/jamanetworkopen.2022.25459.PMID: 36006646
- 501
- 502 24. Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and
 503 its PD-L1 and CD8 status. Camy F, Karpathiou G, Dumollard JM, Magne N, Perrot JL,
 504 Vassal F, Picot T, Mobarki M, Forest F, Casteillo F, Hathroubi S, Froudarakis M,
 505 Peoc'h M.J Immunother Cancer. 2020 Aug;8(2):e000597. doi: 10.1136/jitc-2020506 000597.PMID: 32859740
- 507
- 508 25. Distinct phenotypic states and spatial distribution of CD8⁺ T cell clonotypes in human
 509 brain metastases. Sudmeier LJ, Hoang KB, Nduom EK, Wieland A, Neill SG,
 510 Schniederjan MJ, Ramalingam SS, Olson JJ, Ahmed R, Hudson WH.Cell Rep Med.
 511 2022 May 17;3(5):100620. doi: 10.1016/j.xcrm.2022.100620. Epub 2022 Apr
 512 27.PMID: 35584630
- 513
- 514 26. Immunogenomic analysis of human brain metastases reveals diverse immune
- 515 landscapes across genetically distinct tumors. Álvarez-Prado ÁF, Maas RR, Soukup K,
- 516 Klemm F, Kornete M, Krebs FS, Zoete V, Berezowska S, Brouland JP, Hottinger AF,
- 517 Daniel RT, Hegi ME, Joyce JA.Cell Rep Med. 2023 Jan 17;4(1):100900. doi:
- 518 10.1016/j.xcrm.2022.100900.PMID: 36652909
- 519
- 520
- 521

522 Conflict of Interest

- 523 All authors declare that the research was conducted in the absence of any commercial or 524 financial relationships that could be construed as a potential conflict of interest.
- 525

526 Author Contributions

527 D. W., N. F., P.V. and J. O. designed and prepared the manuscript. D. W., J. B., R. P., Z. S., P. P., AG. K., C. J., A. T.-F., M. R., H. R., D. C., M. S., P. T., P. B., D. H., M. K., R. X., F. E., 528 529 D. K., M. M., L. B., N. F., P. V. and J. O. discussed and reviewed the manuscript. D. W., J. 530 B., R. P., Z. S., P. P., AG. K., C. J., A. F., AG. K., A. T.-F., N. F. and J. O. have performed 531 collection and organization of data. D. W. and A. T.-F. analyzed the data. R. K. provided 532 patient records from the archive of the Charité. H. R., D. C., P. B. and D. H., provided 533 information on histopathology. All authors read and approved the final version of the 534 manuscript.

- 535
- 536 **Funding**
- 537 No funding disclosures.
- 538

539 Acknowledgments

540 We thank Dr. med. Susen Burock for data queries and patient data from the Berlin tumor 541 registry (Berliner Krebsregister). D.W., N. F. and J.O. had full access to all the data in the 542 study and take responsibility for the integrity of the data and accuracy of the data analysis.

543

544 Supplementary Material

- 545 See separate online content file including supplementary figures (eFigure 1-4) and tables
- 546 (eTable 1a-d, eTable 2a-d).

547

548 **Data availability statement**

549 The datasets and R code and the usage of the R packages supporting the conclusions of this 550 study will be made available on Github by the authors and can be downloaded upon request. 551

552 Main Figures and Tables



- 555 **Figure 1:** Flow-chart of exclusion and inclusion criteria and overview of the resulting groups
- 556 of patients of patients with neurosurgically resected brain metastases in this study
- 557 (COHORTS A, B and C) (A) graphical abstract of the study depicting pre- and postoperative
- 558 dexamethasone dosing from day -13 to day +13 in relation to the date of operation (**B**).
- 559
- 560



561 562

Figure 2: Cutpoint selection using maximally selected rank statistics in COHORT A
displayed in A, with an optimal cutpoint for perioperative dexamethasone (pre-operative
plus post-operative cumulative dexamethasone dosage) of 281 mg and for the subcohort
COHORT B with an optimal cutpoint for total or perioperative dexamethasone dosage of
294 mg (B).



	Treatment			
Characteristic	Overall , N = 539 ¹	< 281 mg , N = 402	≥ 281 mg , N = 137	p-value ²
age (years), Median (IQR)	64 (55 – 72)	64 (55 – 72)	65 (56 – 71)	0.74
gender, n (%)				0.99
female	279 (52)	208 (52)	71 (52)	
male	260 (48)	194 (48)	66 (48)	
pre-operative dexa (mg), Median (IQR)	80 (26 – 144)	59 (24 – 115)	216 (144 – 336)	<0.001
post-operative dexa (mg), Median (IQR)	96 (62 – 132)	84 (60 – 110)	156 (108 – 230)	<0.001
peri-operative dexa (mg), Median (IQR)	190 (132 – 283)	160 (114 – 204)	373 (320 – 438)	<0.001
KPS_group, n (%)				0.43
≥70%	326 (62)	246 (63)	80 (59)	
<70%	199 (38)	144 (37)	55 (41)	
Unknown	14	12	2	
number of brain metastases, n (%)				0.062
1	149 (33)	120 (36)	29 (25)	
2	154 (34)	115 (34)	39 (34)	
>2	150 (33)	103 (30)	47 (41)	

		Treat	ment	
Characteristic	Overall , N = 539 ¹	< 281 mg , N = 402	≥ 281 mg , N = 137	p-value ²
Unknown	86	64	22	
extracran.met, n (%)				0.003
no extracranial metastases	288 (55)	230 (59)	58 (44)	
extracranial metastases	237 (45)	162 (41)	75 (56)	
Unknown	14	10	4	
localization of brain metastases, n (%)				0.57
supratentorial	332 (63)	244 (62)	88 (65)	
infratentorial	90 (17)	71 (18)	19 (14)	
supra- and infratentorial	107 (20)	79 (20)	28 (21)	
Unknown	10	8	2	
entity, n (%)				0.40
breast cancer	93 (17)	71 (18)	22 (16)	
colorectal carcinoma	8 (1.5)	4 (1.0)	4 (2.9)	
melanoma	91 (17)	62 (15)	29 (21)	
NSCLC	286 (53)	218 (54)	68 (50)	
oesophageal carcinoma	1 (0.2)	1 (0.2)	0 (0)	
renal cell cancer	26 (4.8)	18 (4.5)	8 (5.8)	

		Treat	ment	
Characteristic	Overall , N = 539 ⁷	< 281 mg , N = 402	≥ 281 mg , N = 137	p-value ²
SCLC	33 (6.1)	27 (6.7)	6 (4.4)	
unknown primary	1 (0.2)	1 (0.2)	0 (0)	
Ki67, n (%)				0.93
< 30	267 (58)	199 (58)	68 (58)	
>/= 30	195 (42)	146 (42)	49 (42)	
Unknown	77	57	20	
PDL1i_TPS, n (%)				0.93
< 30	102 (64)	74 (64)	28 (64)	
>/= 30	57 (36)	41 (36)	16 (36)	
Unknown	380	287	93	
tumor.volume, n (%)				0.59
< 10	146 (43)	109 (43)	37 (40)	
>/= 10	197 (57)	142 (57)	55 (60)	
Unknown	196	151	45	
edema.volume, n (%)				0.091
< 50	151 (46)	118 (49)	33 (38)	
>/= 50	176 (54)	123 (51)	53 (62)	
Unknown	212	161	51	

	Treatment				
Characteristic	Overall , N = 539 ¹	< 281 mg , N = 402	≥ 281 mg , N = 137	p-value ²	
¹ Median (IQR); n (%)					
² Wilcoxon rank sum test; Pears	son's Chi-squared te	est; Fisher's exa	ct test		

588

589 **Table 1a:** Comparison of the two patient groups of interest before propensity score

590 matching within the whole patient cohort ("all") (N=539). The optimal cutpoint value of 281

⁵⁹¹ mg for perioperative dexamethasone was used to dichotomize patients. ²Interquartile range

- 592 (IQR).
- 593

		Treatment		
	Overall, N =	<294 mg , N =	≥294 mg , N =	p-
Characteristic	483 ¹	375	108	value ²
age (years), Median (IQR)	64 (54 – 71)	64 (54 – 71)	65 (55 – 70)	>0.99
gender, n (%)				0.70
female	256 (53)	197 (53)	59 (55)	
male	227 (47)	178 (47)	49 (45)	
pre-operative dexa (mg), Median (IQR)	80 (24 – 144)	60 (24 – 120)	240 (168 – 336)	<0.001
post-operative dexa (mg), Median (IQR)	94 (62 – 132)	84 (60 – 112)	150 (102 – 230)	<0.001
peri-operative dexa (mg), Median (IQR)	187 (132 – 276)	164 (114 – 207)	387 (336 – 452)	<0.001
KPS_group, n (%)				0.49
≥70%	306 (65)	240 (66)	66 (62)	
<70%	164 (35)	124 (34)	40 (38)	
Unknown	13	11	2	
number of brain metastases, n (%)				0.093

	-	Treatment		
	Overall, N =	<294 mg , N =	≥294 mg , N =	p-
Characteristic	483 ¹	375	108	value ²
1	133 (33)	110 (35)	23 (26)	
2	138 (34)	109 (35)	29 (33)	
>2	131 (33)	94 (30)	37 (42)	
Unknown	81	62	19	
extracran.met, n (%)				0.008
no extracranial metastases	270 (57)	222 (61)	48 (46)	
extracranial metastases	200 (43)	144 (39)	56 (54)	
Unknown	13	9	4	
localization of brain				0.25
metastases, n (%)				0.20
supratentorial	298 (63)	225 (61)	73 (69)	
infratentorial	76 (16)	64 (17)	12 (11)	
supra- and infratentorial	100 (21)	79 (21)	21 (20)	
Unknown	9	7	2	
entity, n (%)				0.54
breast cancer	88 (18)	69 (18)	19 (18)	
colorectal carcinoma	7 (1.4)	4 (1.1)	3 (2.8)	
melanoma	75 (16)	53 (14)	22 (20)	
NSCLC	261 (54)	207 (55)	54 (50)	
oesophageal carcinoma	1 (0.2)	1 (0.3)	0 (0)	
renal cell cancer	24 (5.0)	18 (4.8)	6 (5.6)	
SCLC	26 (5.4)	22 (5.9)	4 (3.7)	
unknown primary	1 (0.2)	1 (0.3)	0 (0)	
Ki67, n (%)				0.49
< 30	239 (58)	183 (57)	56 (61)	
>/= 30	175 (42)	139 (43)	36 (39)	

		Treatment		
	Overall, N =	<294 mg , N =	≥294 mg , N =	p-
Characteristic	483 ¹	375	108	value ²
Unknown	69	53	16	
PDL1i_TPS, n (%)				0.63
< 30	96 (68)	76 (69)	20 (65)	
>/= 30	45 (32)	34 (31)	11 (35)	
Unknown	342	265	77	
tumor.volume, n (%)				0.87
< 10	130 (42)	99 (41)	31 (42)	
>/= 10	182 (58)	140 (59)	42 (58)	
Unknown	171	136	35	
edema.volume, n (%)				0.13
< 50	138 (46)	112 (49)	26 (38)	
>/= 50	160 (54)	118 (51)	42 (62)	
Unknown	185	145	40	
¹ Median (IQR); n (%)				

² Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test

594

595 **Table 1b:** Comparison of the two patient groups of interest before propensity score

596 matching within the whole patient cohort ("3months and KPS<50excl") (N=483). The optimal

597 cutpoint value of 281 mg for perioperative dexamethasone was used to dichotomize

- 598 patients.
- 599

	-	Treatment		-
Characteristic	Overall , N = 262 ¹	<281 mg , N = 131	≥281 mg , N = 131	p- value ²
survival, Median (IQR)	10 (3 – 23)	11 (4 – 26)	8 (2 – 17)	0.007
censoring, n (%)	202 (77)	93 (71)	109 (83)	0.019

		Treatment		
	Overall, N =	<281 mg , N =	≥281 mg , N =	p-
Characteristic	262 ¹	131	131	value ²
age (years), n (%)				>0.99
<60	90 (34)	45 (34)	45 (34)	
≥60	172 (66)	86 (66)	86 (66)	
gender, n (%)				>0.99
female	132 (50)	66 (50)	66 (50)	
male	130 (50)	65 (50)	65 (50)	
KPS group, n (%)				>0.99
<70%	106 (40)	53 (40)	53 (40)	
≥70%	156 (60)	78 (60)	78 (60)	
extracranial metastases, n (%)				>0.99
no extracranial metastases	116 (44)	58 (44)	58 (44)	
extracranial metastases ¹ Median (IQR); n (%)	146 (56)	73 (56)	73 (56)	

² Wilcoxon rank sum test; Pearson's Chi-squared test

600

601
Table 1c: Summary of balance for matched data after performing propensity score
 602 matching for COHORT A produced COHORT C. Comparison of covariates after PSM for 603 the whole patient cohort (n=539) with patients dichotomized according to the optimal of 281 mg (patients were grouped in those with <281 mg dexamethasone vs. \geq 281 mg 604 605 dexamethasone in the total perioperative phase (i.e. pre-operative and post-operative 606 period). In total 216 number of observations were 1:1 matched; standard mean differences 607 for unmatched data and matched data are plotted in **eFigure 4 in the supplements**. 608 609

Dependent:			
Surv(survival,			HR (CPH
censoring)	all	HR (CPH univar. analysis)	multivar.analysis)

		63.0		
age, Mean (SD)		(12.1)	1.02 (1.01-1.03, p<0.001)	1.02 (1.01-1.03, p<0.001)
		279		
gender	female	(51.8)	-	-
		260		
	male	(48.2)	1.20 (0.99-1.46, p=0.061)	-
		78.6		
KPS, Mean (SD)		(14.4)	0.97-0.98, p<0.001	0.97-0.99, p<0.001
extracran.met				
(extracranial	Not	288		
metastasis)	present	(54.9)	-	-
		237		
	Present	(45.1)	1.43 (1.15-1.77, p=0.001)	1.32 (1.05-1.64, p=0.016
cut_off_before_and				
_after_281 (total				
perioperative		402		
dexamethasone)	<281 mg	(74.6)	-	-
		137		
	≥ 281 mg	(25.4)	1.52 (1.25-1.85, p<0.001)	1.47 (1.20-1.80, p<0.001)

610

611 Table 2a: Univariable and multivariable Cox proportional regression in the whole

612 patient cohort

- 613 Cox regression analysis of potential prognostic covariates and overall survival for the whole
- 614 patient cohort ("all") (N=539).
- 615
- 616
- 617

Demandent				
Dependent:				
Surv(survival,				HR (CPH
censoring)		all	HR (CPH univar. analysis)	multivar.analysis)
		62.6		
age, Mean (SD)		(12.0)	1.02 (1.01-1.03, p<0.001)	1.02 (1.01-1.03, p=0.001)
		256		
gender	female	(53.0)	-	-
		227		
	male	(47.0)	1.15 (0.94-1.42, p=0.181)	-
		79.8		
KPS, Mean (SD)		(13.5)	0.98 (0.97-0.99, p<0.001)	0.98 (0.97-0.99, p<0.001)
extracran.met				
(extracranial	Not	288		
metastasis)	present	(54.9)	-	-
· · · · ·		237		
	Present	(45.1)	1.38 (1.08-1.76, p=0.009)	1.27 (0.99-1.63, p=0.062)
cut_off_before_and				
after 281 (total				
perioperative		402		
dexamethasone)	<281 mg	(74.6)	-	-
/	Ŭ Ŭ	137		
	≥ 281 mg	(25.4)	1.39 (1.13-1.72, p=0.002)	1.35 (1.09-1.68, p=0.007)

Table 2b: Univariable and multivariable Cox proportional regression in the subcohort

619 "3months and KPS<50excl"

- 620 Cox regression analysis of potential prognostic covariates and overall survival for the
- 621 patient cohort "3months and KPS<50excl" cohort (n=483).
- 622
- 623
- 624

Dependent: Surv(survival. HR (CPH censoring) all HR (CPH univar. analysis) multivar.analysis) 90 age, Mean (SD) <60 (34.4)-1.58 (1.17-2.14, p=0.003) ≥60 (65.6)1.48 (1.10-2.00, p=0.009) f132 gender female (50.4)130 male (49.6)0.95 (0.72-1.25, p=0.706) -<70% 106 KPS, Mean (SD) (40.5)-156 ≥70% (59.5)0.67 (0.51-0.89, p=0.005) 0.67 (0.51-0.89, p=0.005) extracran.met 116 (extracranial Not (44.3)metastasis) present 146 Present (55.7)1.45 (1.09-1.91, p=0.010) 1.54 (1.16-2.05, p=0.003) cut off before and _after_281 (total perioperative 402 dexamethasone) <281 mg (74.6)137 1.43 (1.08-1.88, p=0.012) \geq 281 mg (25.4)1.46 (1.11-1.92, p=0.007)

625

626 **Table 2c: Univariable and multivariable Cox proportional regression in the matched**

627 patient cohort after propensity score matching

628 Univariable and multivariable Cox proportional regression analysis for matched data

629 for the whole patient cohort ("all") (N=539). See also **eFigure 3 and 4**.

630